Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China.
Biomed Res Int. 2022 Aug 16;2022:3168408. doi: 10.1155/2022/3168408. eCollection 2022.
Ovarian cancer is the second common cancer among the gynecological tumors. It is difficult to be found and diagnosed in the early stage and easy to relapse due to chemoresistance and deficiency in choices of treatment. Therefore, future exploring the biomarkers for diagnosis, treatment, and prognosis prediction of ovarian cancer is significant to women in the world. We downloaded data from TCGA and GTEx and used R "limma" package for analyzing the differentially expressed immune-related lncRNA in ovarian cancer and finally got 7 downregulated and 171 upregulated lncRNA. Then, we paired the differentially expressed immune-related lncRNA and constructed a novel lncRNA pairing model containing 7 lncRNA pairs. Based on the cut-off point with the highest AUC value, 102 patients were selected in high-risk group and 272 in low-risk group. The KM analysis suggested that the patients in the low-risk group had a longer overall survival. Future analysis showed the correlations between risk scores and clinicopathological parameters and infiltrating immune cells. In conclusion, we identified an immune-related lncRNA pairing model for predicting the prognosis and immune-infiltrating cell condition in human ovarian cancer, which thus further can instruct immunotherapy.
卵巢癌是妇科肿瘤中的第二大常见癌症。由于化疗耐药和治疗选择不足,早期发现和诊断困难,容易复发。因此,未来探索卵巢癌的诊断、治疗和预后预测的生物标志物对全世界的女性都具有重要意义。我们从 TCGA 和 GTEx 下载数据,并使用 R“limma”包分析卵巢癌中差异表达的免疫相关 lncRNA,最终得到 7 个下调和 171 个上调的 lncRNA。然后,我们将差异表达的免疫相关 lncRNA 配对,并构建了一个包含 7 个 lncRNA 对的新型 lncRNA 配对模型。基于具有最高 AUC 值的截止点,选择了 102 名高风险组患者和 272 名低风险组患者。KM 分析表明,低风险组患者的总生存期更长。进一步的分析显示了风险评分与临床病理参数和浸润免疫细胞之间的相关性。总之,我们鉴定了一个与免疫相关的 lncRNA 配对模型,用于预测人类卵巢癌的预后和免疫浸润细胞状况,从而进一步指导免疫治疗。